Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on OncoCyte, Lowers Price Target to $1.4

Needham Maintains Buy on OncoCyte, Lowers Price Target to $1.4

Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $2.1 to $1.4.

byBenzinga Newsdesk

November 11, 2022

1 minute read

Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $2.1 to $1.4.

Analyst Ratings

Where Larimar Therapeutics Stands With Analysts

By Benzinga Insights

May 18, 11:02 AM

Analysts have provided the following ratings for Larimar Therapeutics (NASDAQ:LRMR) within the last quarter: Bullish Somewhat Bullish Indifferent…

LRMR

Snowflake Gets Price Target Cuts By Analysts Following Q1 Results

By Lisa Levin

May 25, 8:55 AM

Snowflake Inc. (NYSE: SNPW) reported upbeat sales for its first quarter, but issued weak outlook.

SNPW

Analyst Ratings

Analyst Expectations for Shoals Technologies Gr’s Future

By Benzinga Insights

October 20, 10:00 AM

Over the past 3 months, 13 analysts have published their opinion on Shoals Technologies Gr (NASDAQ:SHLS) stock. These…

SHLS

News

‘Yellow Exec Tells Sales Staff Company Will File Bankruptcy Monday’ – FreightWaves

By Benzinga Newsdesk

July 26, 3:45 PM

https://www.freightwaves.com/news/yellow-executive-tells-sales-employees-company-will-file-bankruptcy-on-july-31 Yellow's senior vice president of sales informed her staff on Wednesday that their last day would be

YELL

Needham Maintains Buy on OncoCyte, Lowers Price Target to $1.4

Related Posts

Where Larimar Therapeutics Stands With Analysts

Snowflake Gets Price Target Cuts By Analysts Following Q1 Results

Analyst Expectations for Shoals Technologies Gr’s Future

‘Yellow Exec Tells Sales Staff Company Will File Bankruptcy Monday’ – FreightWaves